Glen Leverson

Glen Leverson

Auto-generated profile, based on publicly available information

Glen Leverson

Department of Surgery, University of Wisconsin, Madison, Wisconsin

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Journal of the American College of Surgeons
Verified
Journal Article
Closed access
DLDevon Livingston-Rosanoff
Devon Livingston-Rosanoff
DFDavid P. Foley
David P. Foley
GLGlen Leverson
Glen Leverson
LWLee G. Wilke
Lee G. Wilke
Kidney transplant recipients with a history of a pre-transplant malignancy (pre-TM) have an increased risk of post-transplant malignancies (post-TM) and suspected inferior long-term outcomes. No large database studies have examined modern day trends and outcomes in this patient population compared with those without a pre-TM. The United Network for Organ Sharing (UNOS) database was queried for primary adult kidney transplant recipients with pre-TM. Outcomes were compared in patients with and without pre-TM from 2004 to 2016 using multivariable Cox proportional hazard analyses (n = 170,684). The rate of kidney transplants in patients with pre-TM increased from <1% of all kidney transplants in 1994 (n = 77) to 8.3% in 2016 (n = 1,329). Pre-TM was associated with development of post-TM (hazard ratio [HR] 1.77 CI 1.68, 1.86), all cause (HR 1.22 CI 1.18, 1.27), and death-censored graft failure (HR 1.08 CI 1.02, 1.15) between 2004 and 2016. The 5-year all cause graft failure rate was 28% for pre-TM patients and 22% for non-pre-TM patients. Pre-TM was associated with decreased patient survival (5-year 80% vs 88% and HR 1.23 CI 1.18, 1.28). Of the deceased, more pre-TM patients died of malignancy (19% vs 11%). Increasing numbers of patients with pre-TM are undergoing kidney transplantation. This analysis indicates that patients with pre-TM are at increased risk of post-TM, graft loss, and decreased overall survival. The study's limitations highlight the need for collaborative database development between transplant and cancer registries to better define the inter-relationship between a pre-TM and cancer survivorship vs freedom from prolonged dialysis.

1 May 2016 in Transplantation
Verified
Journal Article
Closed access
BEBrian C. Eby
Brian C. Eby
RRRobert R. Redfield
Robert R. Redfield
TEThomas M. Ellis
Thomas M. Ellis
GLGlen E. Leverson
Glen E. Leverson
ASAbby R. Schenian
Abby R. Schenian
JOJon Odorico
Jon Odorico
Background Imported pancreata accumulate cold ischemia time (CIT), limiting utilization and worsening outcomes. Flow cytometric crossmatching (FXM) is a standard method to assess recipient and donor compatibility, but can prolong CIT. Single-antigen bead assays allow for detection of recipient donor-specific HLA antibodies, enabling prediction of compatibility through a “virtual crossmatch” (VXM). This study investigates the utility and outcomes of VXM after transplantation of imported pancreata. Methods We retrospectively compared outcomes of 153 patients undergoing pancreas transplantation at our institution over a 3.5-year period. Results Three patient groups were analyzed based on geographic source of the pancreas graft and the type of prospective crossmatch performed: (1) imported VXM-only, n = 39; (2) imported VXM + FXM, n = 12; and (3) local VXM + FXM, n = 102. There were no episodes of hyperacute rejection and 1 episode of early antibody-mediated rejection (<90 days) in the imported VXM group. Death-censored graft survival, patient survival, and rejection rates were comparable among the recipient groups. For pancreata imported from United Network of Organ Sharing regions 3 and 4, proceeding to surgery without an FXM reduced CIT by 5.1 hours (P < 0.001). The time from organ arrival at the hospital to operation start was significantly shorter in the VXM-only group compared with the VXM + FXM group (P < 0.001). Conclusions Virtual crossmatch helps minimize CIT without increasing rejection or adversely affecting graft survival, making it a viable method to increase pancreas graft utilization across distant organ sharing regions.

28 September 2016 in Cancer
Verified
Journal Article
Open access
PDF file
LTLauren J. Taylor
Lauren J. Taylor
CGCaprice C. Greenberg
Caprice C. Greenberg
ALAnne O. Lidor
Anne O. Lidor
GLGlen E. Leverson
Glen E. Leverson
JMJames D Maloney
James D Maloney
RMRyan A. Macke
Ryan A. Macke
BACKGROUND: Previous studies have suggested that esophagectomy is severely underused for patients with resectable esophageal cancer. The recent expansion of endoscopic local therapies, advances in surgical techniques, and improved postoperative outcomes have changed the therapeutic landscape. The impact of these developments and evolving treatment guidelines on national practice patterns is unknown.METHODS: Patients diagnosed with clinical stage 0 to III esophageal cancer were identified from the National Cancer Database (2004‐2013). The receipt of potentially curative surgical treatment over time was analyzed, and multivariate logistic regression was used to identify factors associated with surgical treatment.RESULTS: The analysis included 52,122 patients. From 2004 to 2013, the overall rate of potentially curative surgical treatment increased from 36.4% to 47.4% (P < .001). For stage 0 disease, the receipt of esophagectomy decreased from 23.8% to 17.9% (P < .001), whereas the use of local therapies increased from 34.3% to 58.8% (P < .001). The use of surgical treatment increased from 43.4% to 61.8% (P < .001), from 36.1% to 45.0% (P < .001), and from 30.8% to 38.6% (P < .001) for patients with stage I, II, and III disease, respectively. In the multivariate analysis, divergent practice patterns and adherence to national guidelines were noted between academic and community facilities.CONCLUSIONS: The use of potentially curative surgical treatment has increased for patients with stage 0 to III esophageal cancer. The expansion of local therapies has driven increased rates of surgical treatment for early‐stage disease. Although the increased use of esophagectomy for more advanced disease is encouraging, significant variation persists at the patient and facility levels. Cancer 2017;123:410–419. © 2016 American Cancer Society.

17 November 2022 in Surgery Open Science
Verified
Journal Article
Open access
GSGrigor S. Simitian
Grigor S. Simitian
DHDavid J Hall
David J Hall
GLGlen Leverson
Glen Leverson
ELEntela B. Lushaj
Entela B. Lushaj
ELErik E. Lewis
Erik E. Lewis
JMJames D Maloney
James D Maloney
Anastomotic leak (AL) after minimally invasive esophagectomy (MIE) is a well-described source of morbidity for patients undergoing surgical treatment of esophageal neoplasm. With improved early recognition and endoscopic management techniques, the long-term impact remains unclear. A retrospective review was conducted of patients who underwent MIE for esophageal neoplasm between January 2015 and June 2021 at a single institution. Cohorts were stratified by development of AL and subsequent management. Baseline demographics, perioperative data, and post-operative outcomes were examined. During this period, 172 MIEs were performed, with 35 of 172 (20.3%) complicated by an AL. Perioperative factors independently associated with AL were post-operative blood transfusion (leak rate 52.9% versus 16.8%; p = 0.0017), incompleteness of anastomotic rings (75.0% vs 19.1%; p = 0.027), and receiving neoadjuvant therapy (18.5% vs 30.8%; p < 0.0001). Inferior short-term outcomes associated with AL included number of esophageal dilations in the first post-operative year (1.40 vs 0.46, p = 0.0397), discharge disposition to a location other than home (22.9% vs 8.8%, p = 0.012), length of hospital stay (17.7 days vs 9.6 days; p = 0.002), and time until jejunostomy tube removal (134 days vs 79 days; p = 0.0023). There was no significant difference in overall survival between patients with or without an AL at 1 year (79% vs 83%) or 5 years (50% vs 47%) (overall log rank p = 0.758). In this large single-center series of MIEs, AL was associated with inferior short-term outcomes including hospital length of stay, discharge disposition other than to home, and need for additional endoscopic procedures, without an accompanying impact on 1-year or 5-year survival. In this large, single-center series of minimally invasive esophagectomies, anastomotic leak was associated with worse short-term outcomes including hospital length of stay, discharge disposition other than to home, and need for additional endoscopic procedures, but was not associated with worse long-term survival. The significant association between neoadjuvant therapy and decreased leak rates is difficult to interpret, given the potential for confounding factors, thus careful attention to modifiable pre- and peri-operative patient factors associated with anastomotic leak is warranted.

1 February 2021 in Surgery
Verified
Journal Article
Closed access
NSNicholas A. Schreiter
Nicholas A. Schreiter
AFAlexander Fisher
Alexander Fisher
JBJames R. Barrett
James R. Barrett
AAAlexandra Acher
Alexandra Acher
LSLaura Sell
Laura Sell
DADaniel E. Abbott
Daniel E. Abbott

1 January 2022 in Journal of Surgical Education
Verified
Journal Article
Closed access
DRDivya Ramakrishnan
Divya Ramakrishnan
KLKhanh Van Le-Bucklin
Khanh Van Le-Bucklin
TSTania Saba
Tania Saba
GLGlen Leverson
Glen Leverson
JKJun Hee Kim
Jun Hee Kim
DEDawn M Elfenbein
Dawn M Elfenbein